CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant
CytoMed Therapeutics (NASDAQ: GDTC) has received full approval for its first-in-human Phase I ANGELICA clinical trial using patented allogeneic CAR-T cell therapy against blood and solid tumors. The trial, conducted in collaboration with the National University Hospital of Singapore, is co-funded by the NMRC Clinical Trial Grant. Unlike traditional CAR-T therapies, CytoMed's approach uses gamma delta T cells from healthy donors, potentially improving quality, lowering costs, and increasing accessibility.
Additionally, CytoMed has completed a cash acquisition of a licensed cord blood bank in Malaysia, expanding its strategy into cord blood-derived biologics through its subsidiary, LongevityBank Pte This acquisition provides access to cord blood donated for research and development, supporting CytoMed's focus on cell therapies for aging diseases and regenerative medicine.
CytoMed Therapeutics (NASDAQ: GDTC) ha ricevuto l'approvazione completa per il suo primo trial clinico di Fase I ANGELICA, che utilizza una terapia con cellule CAR-T allogeniche brevettate per il trattamento di tumori ematologici e solidi. Lo studio, condotto in collaborazione con il National University Hospital di Singapore, è co-finanziato dal NMRC Clinical Trial Grant. Diversamente dalle terapie CAR-T tradizionali, l'approccio di CytoMed utilizza cellule T gamma delta da donatori sani, potenzialmente migliorando la qualità, riducendo i costi e aumentando l'accessibilità.
Inoltre, CytoMed ha completato un'acquisizione in contante di una banca di sangue cordonale autorizzata in Malesia, espandendo la sua strategia nei biologici derivati dal sangue cordonale attraverso la sua filiale, LongevityBank Pte. Questa acquisizione fornisce accesso al sangue cordonale donato per la ricerca e lo sviluppo, sostenendo il focus di CytoMed sulle terapie cellulari per le malattie legate all'invecchiamento e la medicina rigenerativa.
CytoMed Therapeutics (NASDAQ: GDTC) ha recibido la aprobación completa para su ensayo clínico de Fase I ANGELICA, que utiliza terapia con células CAR-T alogénicas patentadas contra tumores hematológicos y sólidos. El ensayo, realizado en colaboración con el Hospital Universitario Nacional de Singapur, está cofinanciado por el NMRC Clinical Trial Grant. A diferencia de las terapias CAR-T tradicionales, el enfoque de CytoMed utiliza células T gamma delta de donantes sanos, lo que podría mejorar la calidad, reducir costos y aumentar la accesibilidad.
Además, CytoMed ha completado una adquisición en efectivo de un banco de sangre de cordón autorizado en Malasia, ampliando su estrategia hacia los biológicos derivados de la sangre de cordón a través de su filial, LongevityBank Pte. Esta adquisición proporciona acceso a sangre de cordón donada para investigación y desarrollo, apoyando el enfoque de CytoMed en terapias celulares para enfermedades relacionadas con el envejecimiento y la medicina regenerativa.
CytoMed Therapeutics (NASDAQ: GDTC)는 혈액 및 고형 종양에 대한 특허된 알로겐 CAR-T 세포 치료를 사용하는 사람 대상 제1상 ANGELICA 임상 시험에 대한 전체 승인을 받았습니다. 이 시험은 싱가포르 국립대학교 병원과 협력하여 수행되며, NMRC 임상 시험 기금으로 공동 자금을 지원받습니다. 전통적인 CAR-T 치료법과 달리 CytoMed의 접근 방식은 건강한 기증자로부터의 감마 델타 T 세포를 사용하여 품질 향상, 비용 절감 및 접근성 증가를 도모합니다.
또한 CytoMed는 말레이시아에 있는 인증된 제대혈 은행을 현금으로 인수하여 자회사인 LongevityBank Pte를 통해 제대혈 유래 생물학으로 전략을 확장하였습니다. 이 인수는 연구 및 개발을 위해 기증된 제대혈에 대한 접근을 제공하여 CytoMed의 노화 관련 질병 및 재생 의학에 대한 세포 치료 초점을 지원합니다.
CytoMed Therapeutics (NASDAQ: GDTC) a reçu l'approbation complète de son essai clinique de Phase I ANGELICA, utilisant une thérapie par cellules CAR-T allogéniques brevetées contre les tumeurs sanguines et solides. L'essai, réalisé en collaboration avec l'Hôpital National Universitaire de Singapour, est cofinancé par la subvention NMRC pour les essais cliniques. Contrairement aux thérapies CAR-T traditionnelles, l'approche de CytoMed utilise des cellules T gamma delta provenant de donneurs sains, ce qui peut améliorer la qualité, réduire les coûts et augmenter l'accessibilité.
De plus, CytoMed a complété une acquisition en espèces d'une banque de sang de cordon autorisée en Malaisie, élargissant ainsi sa stratégie vers des biologiques dérivés du sang de cordon à travers sa filiale, LongevityBank Pte. Cette acquisition permet d'accéder à du sang de cordon donné pour la recherche et le développement, soutenant ainsi l'orientation de CytoMed vers les thérapies cellulaires pour les maladies liées au vieillissement et la médecine régénérative.
CytoMed Therapeutics (NASDAQ: GDTC) hat die vollständige Genehmigung für die erste klinische Studie am Menschen in Phase I ANGELICA erhalten, die patentierte allogene CAR-T-Zelltherapie gegen Blut- und solide Tumoren verwendet. Die Studie wird in Zusammenarbeit mit dem National University Hospital von Singapur durchgeführt und wird durch den NMRC Clinical Trial Grant mitfinanziert. Im Gegensatz zu traditionellen CAR-T-Therapien nutzt CytoMeds Ansatz gamma-delta-T-Zellen von gesunden Spendern, was die Qualität verbessern, die Kosten senken und die Zugänglichkeit erhöhen könnte.
Darüber hinaus hat CytoMed eine Barakquisition einer lizenzierten Nabelschnurblutbank in Malaysia abgeschlossen und erweitert damit seine Strategie in Bezug auf nabelschnurblut-abgeleitete Biologika über seine Tochtergesellschaft LongevityBank Pte. Diese Akquisition ermöglicht den Zugang zu für Forschung und Entwicklung gespendetem Nabelschnurblut, was CytoMeds Fokus auf Zelltherapien für altersbedingte Krankheiten und regenerative Medizin unterstützt.
- Received full approval for Phase I ANGELICA clinical trial using allogeneic CAR-T cell therapy
- Co-funding support from NMRC Clinical Trial Grant for the ANGELICA trial
- Innovative approach using gamma delta T cells, potentially improving quality and accessibility of CAR-T therapy
- Completed acquisition of a licensed cord blood bank in Malaysia
- Expanded strategy into cord blood-derived biologics for aging diseases and regenerative medicine
- None.
Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary, LongevityBank Pte Ltd
SINGAPORE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the treatment of various cancers including blood and solid cancers has obtained full approval for its first-in-human Phase I clinical trial (“ANGELICA Trial”) using its patented allogeneic chimeric antigen receptor T cell (“CAR-T cell”) against several blood and solid tumors in collaboration with the National University Hospital (“NUH”) of Singapore. The ANGELICA Trial is co-supported by the Singapore Ministry of Health through the National Medical Research Council (“NMRC”) Office, and MOH Holdings Pte Ltd under the NMRC Clinical Trial Grant Industry Collaborative Trials (CTG-ICT) scheme (MOH-001646). Grant details are confidential.
CAR-T cell therapy is currently an individualised treatment that typically involves taking a patient’s blood cells and modifying these in the laboratory by grafting an artificial protein, known as a chimeric antigen receptor, on the surface of T cells, a type of white blood cells. The modified T cells are then re-infused into the patient to target and destroy cancer cells. Unlike chemotherapy which targets all actively dividing cells including healthy ones, CAR-T cells specifically recognise targets present on cancer cells (antigens) to kill them, thus sparing healthy cells.
The ANGELICA Trial taps on blood drawn from young healthy donors, potentially improving the quality of CAR-T cells manufactured, lowering production costs and increasing patients’ timely access to therapy since they can be produced off-the-shelf en masse.
Current established CAR-T cell therapies use alpha-beta T cells, a type of immune cells which are largely non-transferable between individual human beings due to the high risk of graft-versus-host disease where the graft attacks the host.
CytoMed’s ANGELICA Trial uses a rare subtype of immune cells known as gamma delta T cells which can be modified from healthy donors and re-infused into un-related patients without the need for matching.
Dr Anand Jeyasekharan, lead investigator of the study and Senior Consultant, Department of Haematology-Oncology, National University Cancer Institute, Singapore (NCIS), said: “ANGELICA is a first-in-class innovative approach to allogenic CAR-T cell therapy for solid cancers. This investigator-initiated trial protocol has been carefully developed with a team of experts in early phase trials, CAR-T cells and allogenic transplantation. With the support from the NMRC CTG-ICT, we eagerly look forward to initiating the enrolment of patients with relapsed cancer for whom this may represent a new option for treatment.”
“We are thrilled to collaborate with NUH, and we hope to provide a meaningful contribution to the development of donor blood immuno-therapy for the treatment of advanced solid and haematological (liquid) tumours in Singapore and worldwide,” says Dr Tan Wee Kiat PhD, the Co-CEO and COO of CytoMed Therapeutics.
Chairman Peter Choo commented, “This trial will give significant impetus to CytoMed to forge ahead and develop our repertoire of affordable, allogeneic off-the-shelf immune cell therapies for life-threatening diseases especially cancers.”
The ANGELICA Trial comprises two parts. Part 1 (donor protocol) is ongoing with the recruitment of healthy blood donors at NUH. With the continued collaboration between CytoMed Therapeutics and NUH, Part 2 of the trial (recipient protocol) may now proceed with the recruitment of patients who have advanced cancers that are resistant to standard therapy regimens.
On a separate note, CytoMed has taken over the assets and licence of a licenced cord blood bank in Malaysia using internal cash resources. Please refer to CytoMed’s announcement on July 17, 2024 and October 3, 2024. This acquisition will sharpen CytoMed’s strategy in cell therapies as it now has access to rare and precious cord blood donated for research and development. There is abundant clinical evidence on cord blood-derived biologics for a wide range of aging diseases and regenerative medicine. This new biotechnology arm will be undertaken through CytoMed’s subsidiary, LongevityBank Pte Ltd. The latter is the holding company of IPSC Depository Sdn Bhd which holds the cord blood banking licence issued by the Ministry of Health, Malaysia.
CytoMed will host an earnings conference call to discuss its six months ended June 30, 2024 financial results on October 8, 2024, at 9 a.m. ET (9 p.m. SGT). The investment community may participate in the conference call by tuning into the following Zoom:
https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT
We encourage stakeholders to join the call, particularly if you have any questions regarding this announcement.
In addition, the management team will be available for meetings in New York City from October 28, 2024, to November 1, 2024. Shareholders and potential investors interested in scheduling a meeting can reach out to enquiry@cytomed.sg.
About CytoMed Therapeutics Limited (CytoMed)
Incorporated in 2018, CytoMed was spun off from the Agency for Science, Technology and Research (A*STAR), Singapore’s leading research and development agency in the public sector. It is a biopharmaceutical company focused on harnessing its licensed proprietary technologies, namely gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell, to create novel cell-based allogeneic immunotherapies for the treatment of various human cancers. The development of novel technologies has been inspired by the clinical success of existing CAR-T therapies in treating haematological malignancies, as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumours. For more information, please visit www.cytomed.sg and follow us on Twitter (“X”) @CytomedSG, on LinkedIn, and Facebook
About the National Medical Research Council (NMRC)
The NMRC was established in 1994 to oversee research funding from the Ministry of Health and support the development and advancement of biomedical research in Singapore, particularly in the public healthcare clusters and medical schools. NMRC engages in research strategy and planning, provides funding to support competitive research grants and core research enablers, and is responsible for the development of clinician scientists through awards and fellowships. The council’s work is supported by the NMRC Office which is part of MOH Holdings Pte Ltd. Through its management of the various funding initiatives, NMRC promotes healthcare research in Singapore, for better health and economic outcomes.
Forward-Looking Statements
This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may, "will, "intend," "should," "believe," "expect," "anticipate," "project," "estimate" or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's plans to develop and commercialize its product candidates; the initiation, timing, progress and results of the Company's current and future pre-clinical studies and clinical trials and the Company's R&D programs; the Company's expectations regarding the impact of future COVID-19 outbreak on its business, the Company's industry and the economy; the Company's estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company's ability to successfully acquire or obtain licenses for additional product candidates on reasonable terms; the Company's ability to establish and maintain collaborations and/or obtain additional funding and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.
Contact :
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention :
Evelyn Tan
Chief Corporate Officer, CytoMed Therapeutics Limited;
Chief Executive Officer, IPSC Depository Sdn Bhd
FAQ
What is the ANGELICA trial for CytoMed Therapeutics (GDTC)?
How does CytoMed's (GDTC) CAR-T therapy differ from traditional approaches?
What recent acquisition has CytoMed Therapeutics (GDTC) completed?